Lexeo Therapeutics (LXEO) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
Lexeo Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 7 sold $992K of LXEO stock on the open market.
Get emailed when insiders cluster-buy stocks like LXEO
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
LXEO insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $300K | 7 |
| Q2 2026 | — | 0 | $336K | 3 |
| Q1 2026 | — | 0 | $84K | 2 |
| Q4 2025 | — | 0 | $265K | 15 |
| Q3 2025 | — | 0 | $7K | 1 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 Lexeo Therapeutics, Inc. insiders reported open-market purchases totaling $0, while 7 insiders reported sales totaling $992K. 1 of 28 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Aug 19SEC | Louis Edward TamayoCFO | Sell | 4,11792,907 held (−4%) | $4.91 | $20K | -34.2% | — |
| Aug 19SEC | Richard Nolan TownsendCEO | Sell | 3,345374,472 held (−1%) | $4.95 | $17K | -34.7% | — |
| Aug 19SEC | Jose Manuel OteroCOO | Sell | 1,304136,178 held (−1%) | $4.96 | $6K | -34.9% | — |
| Jul 1SEC | Richard Nolan TownsendCEO | Sell | 25,947377,817 held (−6%) | $4.48 | $116K | -27.9% | — |
| Jul 1SEC | Narinder Pal BhallaChief Medical Officer | Sell | 22,30682,194 held (−21%) | $4.42 | $99K | -26.9% | — |
| Jul 1SEC | Jose Manuel OteroCOO | Sell | 4,666137,482 held (−3%) | $4.48 | $21K | -27.9% | — |
| Jul 1SEC | Louis Edward TamayoCFO | Sell | 4,64197,024 held (−5%) | $4.49 | $21K | -28.1% | — |
| May 20SEC | Richard Nolan TownsendCEO | Sell | 3,342336,764 held (−1%) | $5.06 | $17K | -36.2% | — |
| May 20SEC | Jose Manuel OteroCOO | Sell | 1,302130,088 held (−1%) | $5.07 | $7K | -36.3% | — |
| Apr 7SEC | Richard Nolan TownsendCEO | Sell Plan | 55,000340,106 held (−14%) | $5.69 | $313K | -43.2% | — |
| Feb 20SEC | Richard Nolan TownsendCEO | Sell | 10,173392,483 held (−3%) | $6.38 | $65K | -49.4% | — |
| Feb 20SEC | Jose Manuel OteroCOO | Sell | 3,016125,460 held (−2%) | $6.40 | $19K | -49.5% | — |
| Feb 20SEC | Jose Manuel OteroCOO | Sell | 72163,476 held (−1%) | $9.27 | $7K | -65.2% | — |
| Nov 20SEC | Richard Nolan TownsendCEO | Sell | 1,127240,991 held (−0%) | $9.27 | $10K | -65.2% | — |
| Nov 20SEC | Jose Manuel OteroChief Technical Officer | Sell | 72163,476 held (−1%) | $9.27 | $7K | -65.2% | — |
| Nov 20SEC | Eric AdlerChief Medical Officer | Sell | 61572,646 held (−1%) | $9.27 | $6K | -65.2% | — |
| Nov 20SEC | Jenny RobertsonGeneral Counsel | Sell | 54968,381 held (−1%) | $9.27 | $5K | -65.2% | — |
| Nov 20SEC | Tai Sandi SeeChief Development Officer | Sell | 38665,476 held (−1%) | $9.27 | $4K | -65.2% | — |
| Oct 17SEC | Richard Nolan TownsendCEO | Sell | 12,985242,266 held (−5%) | $8.94 | $116K | -63.9% | — |
| Oct 17SEC | Tai Sandi SeeChief Development Officer | Sell | 3,84465,906 held (−6%) | $8.94 | $34K | -63.9% | — |
| Oct 17SEC | Jenny RobertsonGeneral Counsel | Sell | 3,48668,970 held (−5%) | $8.94 | $31K | -63.9% | — |
| Oct 17SEC | Eric AdlerChief Medical Officer | Sell | 3,34473,299 held (−4%) | $8.94 | $30K | -63.9% | — |
| Oct 17SEC | Jose Manuel OteroChief Technical Officer | Sell | 2,09164,221 held (−3%) | $8.94 | $19K | -63.9% | — |
| Oct 17SEC | Richard Nolan TownsendCEO | Sell | 148242,118 held (−0%) | $9.56 | $1K | -66.2% | — |
| Oct 17SEC | Tai Sandi SeeChief Development Officer | Sell | 4465,862 held (−0%) | $9.56 | $421 | -66.2% | — |
| Oct 17SEC | Jenny RobertsonGeneral Counsel | Sell | 4068,930 held (−0%) | $9.56 | $382 | -66.2% | — |
| Oct 17SEC | Eric AdlerChief Medical Officer | Sell | 3873,261 held (−0%) | $9.56 | $363 | -66.2% | — |
| Oct 17SEC | Jose Manuel OteroChief Technical Officer | Sell | 2464,197 held (−0%) | $9.56 | $229 | -66.2% | — |
Insiders at Lexeo Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Richard Nolan TownsendCEO | — | $656K | Aug 19, 2026 | — |
| Narinder Pal BhallaChief Medical Officer | — | $99K | Jul 1, 2026 | — |
| Jose Manuel OteroCOO | — | $86K | Aug 19, 2026 | — |
| Louis Edward TamayoCFO | — | $41K | Aug 19, 2026 | — |
| Tai Sandi SeeChief Development Officer | — | $38K | Nov 20, 2025 | — |
| Jenny RobertsonGeneral Counsel | — | $37K | Nov 20, 2025 | — |
| Eric AdlerChief Medical Officer | — | $36K | Nov 20, 2025 | — |
LXEO stock: common questions
Are Lexeo Therapeutics, Inc. insiders buying LXEO stock?
In the past 12 months, 0 insiders reported open-market purchases of LXEO worth $0.
Are Lexeo Therapeutics, Inc. insiders selling LXEO stock?
7 insiders reported sales worth $992K over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is LXEO's 52-week range?
Over the past year LXEO has traded between $3.14 and $10.63. It last closed at $3.23 on Oct 9, 2026.